CENGILD MEDICAL BERHAD
KLSE (MYR): CENGILD (0243)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.275
Today's Change
+0.005 (1.85%)
Day's Change
0.265 - 0.275
Trading Volume
335,800
Financial
Market Cap
229 Million
NOSH
834 Million
Latest Quarter
30-Sep-2024 [#1]
Announcement Date
25-Nov-2024
Next Quarter
31-Dec-2024
Est. Ann. Date
27-Feb-2025
Est. Ann. Due Date
01-Mar-2025
QoQ | YoY
163.05% | 11.17%
Revenue | NP to SH
71,539.000 | 11,486.000
RPS | P/RPS
8.58 Cent | 3.20
EPS | P/E | EY
1.38 Cent | 19.96 | 5.01%
DPS | DY | Payout %
0.74 Cent | 2.69% | 53.66%
NAPS | P/NAPS
0.13 | 2.04
QoQ | YoY
3.63% | -13.45%
NP Margin | ROE
16.06% | 10.22%
F.Y. | Ann. Date
30-Sep-2024 | 25-Nov-2024
Latest Audited Result
30-Jun-2024
Announcement Date
30-Oct-2024
Next Audited Result
30-Jun-2025
Est. Ann. Date
30-Oct-2025
Est. Ann. Due Date
27-Dec-2025
Revenue | NP to SH
66,854.000 | 11,085.000
RPS | P/RPS
8.02 Cent | 3.43
EPS | P/E | EY
1.33 Cent | 20.68 | 4.84%
DPS | DY | Payout %
0.74 Cent | 2.69% | 55.60%
NAPS | P/NAPS
0.13 | 2.06
YoY
-16.59%
NP Margin | ROE
16.58% | 9.95%
F.Y. | Ann. Date
30-Jun-2024 | 27-Aug-2024
Revenue | NP to SH
89,156.000 | 16,004.000
RPS | P/RPS
10.70 Cent | 2.57
EPS | P/E | EY
1.92 Cent | 14.32 | 6.98%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
44.38% | 11.17%
NP Margin | ROE
17.95% | 14.24%
F.Y. | Ann. Date
30-Sep-2024 | 25-Nov-2024
Show?
| Last 10 FY Result | ||||||||
| AQR | T4Q | 30/06/24 | 30/06/23 | 30/06/22 | 30/06/21 | CAGR | ||
|---|---|---|---|---|---|---|---|---|
| Revenue | 89,156 | 71,539 | 66,854 | 70,280 | 64,442 | 63,470 | 1.74% | |
| PBT | 22,624 | 16,766 | 15,850 | 17,375 | 12,114 | 13,469 | 5.57% | |
| Tax | -6,620 | -5,280 | -4,765 | -4,086 | -2,723 | -3,464 | 11.20% | |
| NP | 16,004 | 11,486 | 11,085 | 13,289 | 9,391 | 10,005 | 3.47% | |
| - | ||||||||
| NP to SH | 16,004 | 11,486 | 11,085 | 13,289 | 9,391 | 10,005 | 3.47% | |
| - | ||||||||
| Tax Rate | 29.26% | 31.49% | 30.06% | 23.52% | 22.48% | 25.72% | - | |
| Total Cost | 73,152 | 60,053 | 55,769 | 56,991 | 55,051 | 53,465 | 1.41% | |
| - | ||||||||
| Net Worth | 112,361 | 112,361 | 111,360 | 106,138 | 112,021 | 13,779 | 100.55% | |
| Equity | ||||||||
| AQR | T4Q | 30/06/24 | 30/06/23 | 30/06/22 | 30/06/21 | CAGR | ||
|---|---|---|---|---|---|---|---|---|
| Net Worth | 112,361 | 112,361 | 111,360 | 106,138 | 112,021 | 13,779 | 100.55% | |
| NOSH | 833,541 | 833,541 | 832,912 | 832,874 | 818,800 | 599,101 | 11.59% | |
| Ratio Analysis | ||||||||
| AQR | T4Q | 30/06/24 | 30/06/23 | 30/06/22 | 30/06/21 | CAGR | ||
|---|---|---|---|---|---|---|---|---|
| NP Margin | 17.95% | 16.06% | 16.58% | 18.91% | 14.57% | 15.76% | - | |
| ROE | 14.24% | 10.22% | 9.95% | 12.52% | 8.38% | 72.61% | - | |
| Per Share | ||||||||
| AQR | T4Q | 30/06/24 | 30/06/23 | 30/06/22 | 30/06/21 | CAGR | ||
|---|---|---|---|---|---|---|---|---|
| RPS | 10.70 | 8.58 | 8.03 | 8.51 | 8.28 | 10.59 | -8.80% | |
| EPS | 1.92 | 1.38 | 1.33 | 1.62 | 1.46 | 1.67 | -7.30% | |
| DPS | 0.00 | 0.74 | 0.74 | 0.74 | 0.00 | 0.00 | - | |
| NAPS | 0.1348 | 0.1348 | 0.1337 | 0.1285 | 0.144 | 0.023 | 79.70% | |
| Adjusted Per Share Value based on latest NOSH - 833,541 | ||||||||
| AQR | T4Q | 30/06/24 | 30/06/23 | 30/06/22 | 30/06/21 | CAGR | ||
|---|---|---|---|---|---|---|---|---|
| RPS | 10.70 | 8.58 | 8.02 | 8.43 | 7.73 | 7.61 | 1.76% | |
| EPS | 1.92 | 1.38 | 1.33 | 1.59 | 1.13 | 1.20 | 3.48% | |
| DPS | 0.00 | 0.74 | 0.74 | 0.73 | 0.00 | 0.00 | - | |
| NAPS | 0.1348 | 0.1348 | 0.1336 | 0.1273 | 0.1344 | 0.0165 | 100.67% | |
| Price Multiplier on Financial Quarter End Date | ||||||||
| AQR | T4Q | 30/06/24 | 30/06/23 | 30/06/22 | 30/06/21 | CAGR | ||
|---|---|---|---|---|---|---|---|---|
| Date | 30/09/24 | 30/09/24 | 28/06/24 | 30/06/23 | 30/06/22 | - | - | |
| Price | 0.265 | 0.265 | 0.315 | 0.395 | 0.40 | 0.00 | - | |
| P/RPS | 2.48 | 3.09 | 3.92 | 4.64 | 4.83 | 0.00 | - | |
| P/EPS | 13.80 | 19.23 | 23.67 | 24.55 | 33.13 | 0.00 | - | |
| EY | 7.25 | 5.20 | 4.22 | 4.07 | 3.02 | 0.00 | - | |
| DY | 0.00 | 2.79 | 2.35 | 1.87 | 0.00 | 0.00 | - | |
| P/NAPS | 1.97 | 1.97 | 2.36 | 3.07 | 2.78 | 0.00 | - | |
| Price Multiplier on Announcement Date | ||||||||
| AQR | T4Q | 30/06/24 | 30/06/23 | 30/06/22 | 30/06/21 | CAGR | ||
|---|---|---|---|---|---|---|---|---|
| Date | 25/11/24 | 25/11/24 | 27/08/24 | 24/08/23 | 25/08/22 | - | - | |
| Price | 0.27 | 0.27 | 0.285 | 0.42 | 0.475 | 0.00 | - | |
| P/RPS | 2.52 | 3.15 | 3.55 | 4.94 | 5.73 | 0.00 | - | |
| P/EPS | 14.06 | 19.59 | 21.41 | 26.11 | 39.35 | 0.00 | - | |
| EY | 7.11 | 5.10 | 4.67 | 3.83 | 2.54 | 0.00 | - | |
| DY | 0.00 | 2.74 | 2.60 | 1.76 | 0.00 | 0.00 | - | |
| P/NAPS | 2.00 | 2.00 | 2.13 | 3.27 | 3.30 | 0.00 | - | |
PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.
NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.
Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.
All figures in '000 unless specified.
Discussions
1 person likes this. Showing 50 of 251 comments
The PAT quite consistent
Low gearing at 0.26
Not sure how is the Oncology JV announced in Jul23 seen not contributing to revenue.
Revenue also stagnant not much improvement.
2023-11-24 20:26
this counter are down trend. up abit then contiune drop . careful. why not move other uptrend stock ?
2023-12-06 21:27
company is doing ok but its expansion is too slow. It was listed on 2022-4-18. Its IPO proceeds should be used for expansion within 3 years. According to its latest quarterly report, its IPO money is hardly used more than one and half year later.
2023-12-07 13:10
Haha, cengild buying property instead of investing in medical business, wtf! Private placements or rights issues soon…DUMP!!!
2024-01-01 19:50
They never heard abt leasing? The same thing that they doing now so successfully. Buying a property? No need take into refurbishment and maintenance cost??? Something damn fishy…can smell from afar. The board members who agreed on this shud be sacked.
2024-01-01 20:00
Yes, it supposed to be an asset light business model. To have a hospital set-up, it is costly to operate with gestation period of 3 to 5 years upon completion. Focus should be to build its business since it is relatively new healthcare group that was established in 2017
2024-01-04 09:53
This acquisition should be scrapped. The management should re-think again of its business model. It is costly to operate a hospital without relevant expertise due to its high fixed overhead & capital expenditure & it is an impediment for its to scale up. In total RM180m needs to commit to this expansion plan
2024-01-04 15:51
the next few years (until 2027) are not going to be exciting due to growing pains. If I were you, I would sell now and buy back later
2024-01-05 10:20
SHOB
put it in my safe box see after in mid june
1 week ago
Yup...Invested...@0.32...🤓
2024-01-15 19:49
The worst performing healthcare in Bursa with almost 50% contraction. I believe many shareholders have doubt of the recent Proposed Acquisition and change of business model from asset light to heavy
2024-02-02 16:49
first time for many years, I see a healthcare counter that down so much. Typically, healthcare companies should be the most resilient counters
2024-02-02 16:52
CENGILD has been heavily mispriced. There is no reason for the overreaction in the sell-off.
The pivot from renting a building to totally owning one seems highly rationale, given there is a huge business risk if the landlord takes back the property.
As a shareholder, decision to own a building MUST be executed and thoroughly supported. Otherwise, there is a huge cloud of uncertainty with high risks of pushing the company into zero revenue if the building lease cannot be renewed.
2024-02-07 23:03
i think they should not buy a new building but instead go for a long term lease
2024-02-08 07:41
They have a bad management team that wobbling around about their business strategy. light business model is a good strategy like in the case of Qualitas and Mediviron with high EBITDA. As a small Group with track record of 2017, it is bad strategy to commit such a high capital expenditure
2024-02-08 16:45
If this Group is already been more than a decade long, then it is fine but not now. It is a high risk strategy at current juncture as they are still figuring the building blocks
2024-02-08 16:46
Mr Warchest, who says Qualitas and Mediviron have a high EBITDA. Their structure is weak, especially Mediviron, and not sustainable. Cengild GI Medical Centre is much better.
2024-02-20 10:57
The passing of Dato Dr K L GOH last year ,was a big blow to the Cengild GI Centre.
But now , they still have a very capable team of doctors there.
2024-02-20 16:41
Good or not, you can analysis both Qualitas & Mediviron business models and financials. You can buy their documents via SSM. So far Cengild is still wobbling with their financials and business model
2024-02-22 11:09
The stock regains its momentum after a short consolidation. (0.30, upon writing)
2024-02-22 15:56
Xi wants to build China industrial industry is so competitive that others simply can't compete with it. Companies still have to invest in China if they want to keep their costs down maintaining their profit margins. At the same time China dominates EV cars industry, solar industry and catching up on chip ...
China takes over the US in terms of nominal GDP is not a matter of if but when. Interesting time ahead.
2024-03-07 00:08
Ya, it is useless now , since they are on the way to change a light assets business model to a heavy assets business model...
2024-07-28 14:45
They just follow the same model as CVSKL but specialise in Gastrointestinal & Liver Disease
2024-07-31 11:07
But CVSKL still rented their space. But still they are much more profitable than Cengild. the management team of Cengild is not capable of growing the business but yet not prudent on the Capex spending
2024-07-31 11:10
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
1
Stock Market Enthusiast
Top 3 AI/Data Center Newsflow for the 3rd Week of December - #TENAGA, #YTL, #YTLPOWER
2
Rakuten Trade Research Reports
3
save malaysia!
4
Good Articles to Share
5
Good Articles to Share
6
Good Articles to Share
Gaza ceasefire deal 'closer than ever', says Hamas and two allies
7
Good Articles to Share
Ryan Serhant makes bold pitch to fix the housing ‘affordability crisis’
8
Good Articles to Share
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
cytew
Reversal of trend is intact now..
2023-11-10 07:36